Abstract Atopic dermatitis (AD) is a chronic inflammatory skin condition with complex etiology that is dependent upon interactions between the host and the environment. Acute skin lesions exhibit the features of a Th2-driven inflammatory disorder, and many patients are highly atopic. The skin barrier plays key roles in immune surveillance and homeostasis, and in preventing penetration of microbial products and allergens. Defects that compromise the structural integrity or else the immune function of the skin barrier play a pivotal role in the pathogenesis of AD. This article provides an overview of the array of molecular building blocks that are essential to maintaining healthy skin. The basis for structural defects in the skin is discussed in relation to AD, with an emphasis on filaggrin and its genetic underpinnings. Aspects of innate immunity, including the role of antimicrobial peptides and proteases, are also discussed.
Introduction
Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that is highly pruritic. Recent population-based studies in the US have estimated the prevalence of AD at over 10 % in both children and adults [1, 2] . While the disease often starts early in infancy, the majority of cases will resolve spontaneously; however, disease may progress into adulthood and can be debilitating. The majority of patients, including those with the most severe form of disease, are highly atopic as judged by markedly elevated levels of serum total IgE and sensitization to multiple allergens from diverse sources, including allergens and skin-colonizing microbes. The etiology of AD is multi-faceted and involves complex gene/environment interactions that conspire to undermine the first line of host defense, namely the skin.
The general view is that AD develops through Th2-driven inflammatory processes; however, T-cell infiltrates within AD skin lesions contain both Th1 and Th2 cells as well as other T cell subtypes ( Fig. 1) [3] . Priming of an array of antigenpresenting cells in the skin by environmental and microbial triggers, or else by epithelial cell-derived cytokines such as TSLP and IL-33 that are secreted directly in response to these triggers, contributes to the T cell response and consequent inflammatory networks. Here, we provide an overview of the factors that compromise the structural and functional integrity of the skin barrier in AD, thereby serving to initiate and perpetuate inflammation at this site.
Barrier Defects and the Epidermis
The Epidermis
Most of the barrier defects that have been described in AD originate in the stratum corneum, the outermost layer of the epidermis. The skin provides a physical barrier against environmental insults and water loss. Both the epidermis and dermis are highly innervated and contain both resident and infiltrating immune cells. The stratified and multi-layered epidermis comprises four sub-layers, which include the basal stratum germinativum, stratum spinosum, stratum granulosum and top-most stratum corneum (Fig. 2) . Keratinocytes, the predominant cell type in the epidermis, are anchored to the basement membrane by complex multi-protein structures called hemidesmosomes and to adjacent keratinocytes by desmosomes. The skin is in a perpetual state of self-renewal. As keratinocytes migrate through the epidermis, they undergo proliferation, differentiation and finally cell death or cornification. Within the spinous layer, keratinocytes lose their mitotic ability, change their keratin profile and acquire lamellar Fig. 1 Schematic of the immune response in AD skin lesions. Defects in the epithelial barrier provide a portal of entry for microbial products and allergens. In conjunction, these antigens trigger the innate response through induction of cytokines from the epithelium. Together, these events orchestrate the induction of Th2 cells, which secrete IL-4, IL-5, IL-13 and IL-31, production of IgE, and activation of basophils and mast cells. This process is highly dynamic and evolves to include heterogeneous T-cell types including Th1 cells The expanded view provides a schematic representation of the distribution of structural proteins and components of the innate immune system in the uppermost layers of the epidermis granules, which contain a variety of lipid precursors and enzymes. Upon arrival in the granular layer, keratinocytes become dehydrated, lose their cellular organelles and undergo further change in their protein profile in preparation for cornification. Importantly, the granular layer keratinocytes contain keratohyalin granules, which carry structural proteins and their precursors such as loricrin and profilaggrin. Within the granular layer, lamellar granule contents are secreted to form the lipid layer or tight hydrophobic seal within the stratum granulosum and stratum corneum. The granular layer keratinocytes eventually undergo cell death or cornification to form flattened corneocytes embedded in a hydrophobic lipid matrix to form the top-most impermeable cornified stratum corneum. Corneocytes are surrounded by a cornified envelope, which is assembled from transglutaminase crosslinked proteins and lipids, including the major components, loricrin and involucrin. Finally, individual corneocytes are shed by desquamation, a process that maintains epidermal homeostasis by counterbalancing regeneration within the basal layer.
The Multi-Faceted Filaggrin Story
The structural protein, filaggrin, is critical to corneocyte formation in the stratum corneum. The filaggrin gene, FLG, encodes the 400-kDa precursor polyprotein, profilaggrin, which contains 10 to12 filaggrin repeats. Monomeric filaggrin, which is produced by dephosphorylation and proteolytic cleavage of profilaggrin, aggregates and binds to keratin and other filament proteins to condense keratin bundles in the keratinocyte cytoskeleton. This process facilitates keratinocyte collapse resulting in flattened corneocytes. As such, filaggrin is critical to maintaining the physical strength of the stratum corneum and minimizing entry of foreign antigens and transepidermal water loss (TEWL). In addition to this important attribute, filaggrin helps to maintain an acidic pH in the skin by undergoing further processing in the upper stratum corneum to release free amino acids, thereby inhibiting bacterial growth.
Filaggrin Mutations More than 30 years ago, filaggrin was implicated in the skin disease ichthyosis vulgaris, an autosomal semidominant disorder of keratinization [4] . In 1996, reduced filaggrin levels were reported in AD skin [5] ; however, the mechanism underlying this observation was not described until a decade later owing to the complexity of the FLG gene. FLG is a polymorphic gene comprising two small exons and a very large third exon. The third exon contains 10-12 tandem repeats of the filaggrin sequence, which prevented researchers from solving its sequence using conventional PCR techniques. Finally, in 2006 the sequence of FLG was solved using exhaustive PCR amplification of overlapping short sequences that were then used to construct the full length sequence of exon 3 [6] . This work identified two loss-offunction (null allele) mutations, R501X and 2282del4, that were associated with ichthyosis vulgaris. At the same time, these mutations, which result in truncated protein products, were also shown to be a major predisposing factor for AD [7] [8] [9] . Notably, individuals harboring these mutations had disease that was early onset, more persistent and associated with atopy [10] [11] [12] [13] The variable number of repeats encoding filaggrin monomer within FLG exon 3 may also contribute to decreased levels of filaggrin in AD skin. Consistent with this view, intragenic copy number variation in FLG contributes to disease severity as evidenced by lower copy numbers in AD patients as compared with controls [16] . In addition, methylation of FLG was recently shown to add to disease risk associated with null variants, thereby establishing a potential interaction between epigenetic and genetic factors in determining disease outcomes [17] .
Several lines of evidence now support a role for FLG mutations and genetic variations in promoting perturbation of the skin barrier at the cellular level. These include an association between FLG genotype or deficiencies in filaggrin, and disorganized keratin filaments, abnormal bilayer architecture, impaired lipid profiles and altered acidification pathways in skin [18] [19] [20] . Other studies have demonstrated effects on TEWL and hydration [21, 22] . Deficiencies in filaggrin protein may extend beyond structural impairment to the immune system through effects on proinflammatory cytokines. Increased IL-1 expression has been reported in the stratum corneum of AD patients with FLG mutations as compared to those lacking FLG mutations [23] . Similarly, in a mouse model, filaggrin deficiency has been implicated in induction of the Th2-promoting cytokine TSLP in keratinocytes [24] .
Filaggrin By-products In healthy skin, filaggrin is degraded by the cysteine peptidase, caspase-14, and other proteases into natural moisturizing factors (NMF) [25] . These include free amino acids, urocanic acid and pyrrolidine carboxylic acid. NMFs work to balance moisture, pH and buffering capacity, thereby strengthening the stratum corneum barrier not only against environmental insults such as allergens and chemical pollutants, but also against colonization or infection by bacteria and other pathogens. Reduced NMF levels have been reported in AD patients carrying FLG mutations as compared with their counterparts lacking these mutations [21, 26, 27] .
Filaggrin Deficiency and Antigen Co-exposure Not all subjects who harbor FLG mutations develop disease. Conversely, not all AD patients carry FLG mutations. Thus, despite the evidence of a role for filaggrin, other factors clearly influence the path to disease.
In filaggrin-deficient or filaggrin-null mouse models, a compromised skin barrier is not sufficient to induce AD. In these mice, percutaneous co-exposure to allergens or protein antigens such as ovalbumin or topical haptens and a resultant IgE-mediated immune response appears to be required [28] [29] [30] [31] . A common feature of these models was an enhanced percutaneous immune response, suggesting enhanced antigen penetration. However, it is not clear whether this phenomenon translates to humans. For example, filaggrin knock-down alone did not affect the permeability, lipid organization or composition of the stratum corneum in an ex vivo human skin model [32] . Moreover, in AD patients with and without FLG mutations who were sensitized on healthy skin by cutaneous application of 2,4-dinitrochlorobenzene (DNCB), equal penetration of the skin and similar Th2 skewed DNCB-specific T cell responses were observed between groups [33] . By contrast, other work supports an interaction between FLG mutations and allergen exposure. Among children who were monitored for the first 8 years of life, exposure to cat in early life significantly enhanced the risk of developing eczema associated with FLG mutations [34] . Further work is clearly warranted to understand how FLG mutations impact antigendriven immune responses through the skin.
Immune Modulation of Filaggrin Acute skin lesions in AD exhibit the hallmarks of Th2-driven inflammation including high expression of TSLP in the epithelium and the presence of Th2 cells expressing IL-4 and IL-13 and basophils [35, 36] . Recent evidence supports a role for Th2-associated factors in regulating filaggrin expression. In human skin models and keratinocyte cultures, histamine and a variety of cytokines including IL-4, IL-17, IL-22, IL-25 and IL-31 have been shown to decrease filaggrin production or else repress FLG gene expression [37] [38] [39] [40] [41] [42] [43] . Certain cytokines may modulate expression of filaggrin levels indirectly, as evidenced by cytokine-mediated downregulation of proteases involved in the processing of profilaggrin (see below). Evidence of an interaction between genetic polymorphisms in IL-10 and IL-13 with the 2284del4 FLG mutation and enhanced risk of AD supports the view that the interplay between cytokines and filaggrin levels in the skin is complex [44] .
Filaggrin-like Proteins Expression profiles of filaggrin and filaggrin-like proteins continue to be elucidated in healthy and diseased skin. Deficiencies in epidermal filaggrin-like proteins, filaggrin-2 and hornerin, have recently emerged in AD [45, 46] . Genes encoding these proteins, along with filaggrin, map to the epidermal differentiation complex on human chromosome 1q21, which comprises a large number of genes involved in maturation of the epidermis. Similar to filaggrin, filaggrin-2 belongs to the S100 fused-type protein family and shares many molecular attributes with filaggrin. Two premature stop codon mutations in FLG2, designated rs12568784 and rs16833974, have recently been associated with more persistent AD [47] . Recently, a single nucleotide polymorphism in the hornerin gene, HRNR (rs877776), was reported in German but not Irish patients with AD [48, 49] .
Other Proteins in the Stratum Corneum Corneocytes in the uppermost epithelial layer are surrounded by a cornified envelope and attached to adjacent corneocytes by corneodesmosomes. In addition to highly reduced compaction of corneocytes in AD skin, there is evidence of defects in the cornified envelope [50] . The corneodesmosomal proteins desmoglein-1, desmocolin-1 and corneodesmosin are expressed at lower levels in AD lesional skin than non-lesional skin [45] . Also, the staining patterns of corneodesmosomal proteins have been shown to be abnormally diffuse [51] . In addition, loricrin and involucrin are expressed at lower levels in AD skin as compared with healthy skin [50, 52, 53] . In a mouse model, combined deficiencies in the scaffold proteins of the cornified envelope, involucrin, envoplakin and periplakin, resulted in hyperkeratosis, as well as decreased lipid content and reduced proteases resulting in defective filaggrin processing. Moreover, cellular infiltrates of CD4 + T cells and γδ T cells were evident [54] . In human keratinocyte cultures, expression of corneodesmosome and cornified envelope proteins is decreased by Th2-associated factors including IL-4, IL-13 and histamine, suggesting that the inflammatory milieu in AD skin compromises the cornified envelope [37, 53] .
The Lipid Bilayer
Hydrophobic lipids form the 'mortar' of the stratum corneum and serve to strengthen and maintain hydration of the epidermal barrier. Keratinocytes in the stratum granulosum release lipid precursors and lipid-processing enzymes from their lamellar granules in the uppermost layers of the epidermis. The predominant lipid precursors comprise glycosylceramides, sphingomyelin and phospholipids, which are enzymatically processed to form ceramides, cholesterol and free fatty acids. In healthy skin, ceramides constitute the predominant lipids. Early evidence implicating the lipid bilayer in compromised barrier function in AD came from electron microscopy studies that revealed disturbed or incomplete lamellar body maturation and extrusion [55, 56] . Since that time, several studies have convincingly demonstrated not only decreased levels of ceramides but also changes in ceramide composition or in the ceramide:cholesterol ratio in AD skin [57] [58] [59] . In addition, to these quantitative changes in lipid composition, the fatty acids and ceramides found in AD skin have a shorter chain length than in normal skin, which may enhance the permeability of the skin barrier [60, 61] . These abnormalities have been correlated with abnormal lipid organization in the stratum corneum of AD patients as judged by electron diffraction studies [60, 62] . Decreased ceramide levels in AD skin might arise from increased expression of lipid-processing enzymes such as sphingomyelinase and sphingomyelinase deacylase, or else from expression of novel enzymes such as glucosylceramide deacylase [63] [64] [65] . Beyond these aspects, other studies have implicated the immune system in altering lipid metabolism in AD. In a human ex vivo skin model, IL-4 and IL-6 decreased ceramide levels, while IFN-γ and TNF-α had the opposite effect [66] . However, in other work, IFN-γ decreased ceramides with long chain fatty acids suggesting that it may contribute to altered ceramide profiles in AD skin [67] . IFN-γ can be expressed at high levels in AD skin wherein it mediates enhanced apoptosis of keratinocytes in a Fas-dependent manner [68] . Thus, this cytokine acts through multiple pathways to undermine the skin barrier.
Tight Junctions
Tight junctions are highly complex structures that form a paracellular barrier to tightly regulate passage of solutes in a highly selective fashion across the epithelium [69] . The components of tight junctions include claudins, occludins, tricellulin, zonula occludens and junction adhesion molecules. Among these, the claudin (CLDN) family of proteins, which consists of more than 20 proteins, is pivotal to tight junction formation. Within the skin, the composition of tight junction complexes differs in different layers of the epidermis. Moreover, as knowledge of tight junctions has evolved, it has become clear that these complexes fulfill functions beyond their structural role. These aspects are beyond the scope of this article and are reviewed elsewhere [70] .
In healthy skin, Langerhans cells are able to sample antigens that have gained access through the stratum corneum by extending their dendrites to penetrate tight junctions between keratinocytes [71] . This remarkable adaptability facilitates immune surveillance while maintaining integrity of the skin barrier. The majority of AD patients who are atopic are sensitized to dust mite. Furthermore, IgE antibodies to microbial products derived from skin-colonizing organisms can be detected in the serum of these patients, suggesting that the skin acts as a portal for enhanced antigen entry [72, 73] . The cysteine protease dust mite allergen, Der p 1, has the capacity to cleave occludin, and putatively claudin-1, thereby breaching tight junctions at epithelial surfaces [74] . Similarly, in an ex vivo model of porcine skin that was infected using Staphylococcus spp., disruption of tight junctions was evidenced by downregulation of a variety of proteins including occludin and zonula occludens-1, coupled with an increase in transepidermal resistance [75] . Reduced levels of CLDN1 in AD skin, or else in human keratinocytes, have been inversely correlated with expression of Th2 markers and a propensity to infection with herpes simplex virus 1 [76•, 77] . Together, these findings support a key role for reduced CLDN1 in immune dysregulation and susceptibility to infection in AD.
Antimicrobial Peptides
The skin provides the first outpost of the immune system. As such, its ability to mount an innate response to invading pathogens is pivotal to the host's wellbeing. In AD patients, the prevalence of skin colonization with Staphylococcus spp. is high. Furthermore, a subset of patients is predisposed to develop eczema herpeticum, a disseminated infection with herpes simplex virus. These features of the disease point to critical defects in the innate response. Antimicrobial peptides (AMPs), which target bacteria, fungi and viruses, are integral to this response. AMPs are small cationic proteins that permeabilize microbial membranes through interactions with anionic components, resulting in microbial lysis. Specific AMPs target specific pathogens by virtue of their charge and structure, which dictate the mechanism of microbial killing. In addition to their direct antimicrobial activity, AMPs also recruit inflammatory cells and stimulate expression of cytokines and chemokines. Whereas in healthy skin AMPs are produced by keratinocytes, they are produced by a variety of cell types in inflamed skin, including infiltrating neutrophils and resident mast cells [78] . AMPs can be subdivided into several families, among which β-defensins and cathelicidins are the most highly elucidated. In humans, β-defensin-1 (hBD-1) is constitutively expressed, while hBD-2 and hBD-3 are induced in response to inflammatory stimuli, via Toll-like receptor signaling pathways. A complete list of AMPs in human skin is described elsewhere [78] .
The role of AMPs in AD skin is complex and controversial. Initial studies aimed at understanding the role of AMPs in AD questioned why AD patients are more prone to colonization by microbial pathogens than those with psoriasis. Comparison of messenger RNA or protein levels of AMPs in lesional skin from patients with AD and psoriasis revealed markedly lower expression of the cathelicidin LL-37 as well as hBD-2 in AD skin [79, 80] . Other studies that focused on hBD-3, and dermcidin, an AMP found in sweat glands, supported these observations [81, 82] . Decreased LL-37, hBD-2 and hBD-3 have also been reported in the skin of AD patients colonized by herpes simplex virus compared with non-colonized patients [83, 84] .
On the other hand, there is a body of work to support the view that AMPs are actually induced in AD skin. Higher levels of LL-37 have been reported in lesional versus nonlesional AD skin [85] . Similarly, increased hBD-2, hBD3 and RNase 7 have been shown in AD skin as compared to healthy skin at the mRNA or protein level [86, 87] . Such discrepancies may relate to injury at the skin biopsy site. For example, tape stripping can enhance expression of a variety of factors including psoriasin, RNase 7, hBD-2 and hBD-3 in lesional skin [88, 89] . Other contributing factors might include the atopic status of the patient, bacterial colonization profiles of the skin at the time of biopsy, chronicity of the lesion, the type of skin specimen obtained (partial or full thickness) and the methods used to identify AMPs.
While there is evidence of decreased activity of AMPs in AD skin, it is not clear whether this results from decreased production or else decreased mobilization from keratinocytes with a consequent impairment in microbial killing [90] . In addition, genetic factors may also contribute. Though various single nucleotide polymorphisms in DEFB1, the gene encoding hBD-1 have been associated with AD, the functional relevance of such genetic variations is not clear [91, 92] . In order to better understand the mechanisms controlling levels of AMPs in the skin, investigators have explored the modulatory properties of cytokines. The Th2 cytokines, IL-4 and IL-13 can inhibit hBD-2 and hBD-3 gene expression by keratinocytes in vitro [81] . Furthermore, antibody-mediated neutralization of IL-4, IL-10 and IL-13 enhanced expression of LL-37, hBD-2 and hBD-3 in skin explant cultures from AD patients [79, 93, 94] . Notably, inhibition of IL-4 and IL-13 also inhibited replication of vaccinia virus in keratinocyte cultures [79] . This key observation suggests that Th2 cytokine expression in the skin contributes to the risk for developing eczema vaccinatum in AD patients following viral inoculation. Interleukin-33 is a newly described cytokine that is expressed by epithelial cells and activates a variety of cell types including Th2 cells and mast cells. Inhibition of seruminduced hBD-2 in human keratinocyte cultures has recently been described [95] . Collectively, these observations highlight the complexity of expression and regulation of AMPs in AD skin.
Proteases and Their Inhibitors
Proteases and their inhibitors are central to barrier homeostasis by maintaining the desquamation process. They aid in the degradation of the corneodesmososmes, which tether adjacent corneocytes, thereby facilitating detachment of the corneocytes from the stratum corneum without compromising the integrity of the skin barrier. Proteases also act to regulate levels of lipid-processing enzymes and antimicrobial peptides, and are involved in chemotaxis, cytokine expression, inflammation, tissue repair and apoptosis. Among the extensive array of proteases expressed in skin, those that have been most frequently implicated in AD are the kallikreins (KLK). These serine proteases mediate their functions through activation of G-protein coupled protease-activated receptors (PARs) expressed on a broad array of cell types. Perturbation of protease production and activation appears to lead to abnormal desquamation and breakdown of lipid-processing enzymes and AMPs. Several studies point to aberrant expression and enhanced enzymatic activity of kallikreins in AD skin [96] [97] [98] . Genetic studies have identified a 4-bp insertion in the 3'untranslated region of the KLK7 gene, which is associated with AD, but only in those patients who have lower serum IgE levels [99] . However, in another study, the same insertion in KLK7 was not linked to AD [100] . KLK5 binds to PAR-2, which is expressed at high levels on primary afferent nerve fibers and keratinocytes in AD skin biopsies. This receptor mediates itch, as well as upregulation of ICAM-1, and the production of proinflammatory cytokines in animal systems [101, 102] . Furthermore, in cultures of normal human keratinocytes, IL-4 and IL-13 can enhance the expression and activity of KLK7, suggesting that Th2 cytokines themselves contribute to kallikrein dysfunction [103] . Other proteases that have been implicated in AD include the cysteine protease cathepsins. Cathepsin V levels are decreased in AD skin lesions, and this is linked to increased expression of cystatin M/E, which exerts antiprotease activity [104] . However, in animal models, both decreased and increased expression of cathepsins leads to inflammatory responses in the skin akin to those in AD [105, 106] . Caspase-14 is a cysteine peptidase that is expressed primarily in keratinocytes and plays a role in terminal differentiation. Caspase-14 was recently shown to process filaggrin monomers and degrade filaggrin, resulting in the production of NMFs [25] . Deficiencies in caspase-14 in AD skin have been observed; however, how this may relate to inflammatory responses remains to be determined [107] .
The importance of protease inhibitors in maintaining the skin barrier is evidenced by Netherton syndrome, an autosomal recessive disorder resulting from a loss-of-function mutation in the SPINK5 gene [108] . This gene encodes the protease inhibitor lymphoepithelial Kazal-type related inhibitor (LEKTI), which, among other proteases, targets KLK5 and KLK7. Individuals affected by this syndrome develop severe AD and allergic symptoms arising from dysregulated protease activity. This results in thinning of the stratum corneum and markedly increased production of TSLP by epithelial cells via the KLK5/PAR2 axis [109, 110] . Several genetic studies have linked single nucleotide polymorphisms in SPINK5 to atopy and AD; however, the data are conflicting [111] [112] [113] [114] . Loss-of-function mutation in SPINK5* [108] ; SNPs in SPINK5* [111] [112] [113] [114] Causes severe AD associated with Netherton syndrome*; thinning of stratum corneum and ↑ TSLP* §# [109, 110] Reported in AD patients* and ichthyosis vulgaris patients ¶ . Reported in ex vivo skin models † and epithelial/keratinocyte cultures § . # Reported in animal models. Italics denote the predicted effect on skin, though this has not been demonstrated experimentally.
TEWL, transepidemal water loss.
Conclusions and Future Directions
There is overwhelming evidence that defects in the skin barrier contribute to the pathogenesis of AD (Table 1) . While the discovery of filaggrin mutations represents a major advance in our understanding of the disease, it does not tell the whole story. Barrier defects are determined by a constellation of host and environmental factors. In addition to reduced levels of filaggrin, irregularities in other structural proteins conspire to compromise the skin barrier, thereby facilitating antigen entry and the breakdown of host defenses. Deficiencies in innate immunity further undermine the skin barrier and increase the propensity for infection and aberrant adaptive immune responses. Understanding how these events unfold over time will be pivotal to identifying new molecular targets for therapy. Topical treatments that restore the skin barrier in AD are an important modality in the armory against AD. Incorporation of recombinant filaggrin monomers is one approach currently being tested in animal models [115] . As we learn more about the skin barrier and its defects in AD, we can anticipate new developments in topical therapies for this debilitating disease.
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